Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 7, Issue 6, 2008, Pages 390-397

  Cartwright, Thomas ^a,b   Kuefler, Paul ^a,c   Cohn, Allen ^a,d   Hyman, William ^a,e   Berger, Maury ^a,b   Richards, Donald ^a,e   Vukelja, Svetislava ^a,e   Nugent, John E ^a,f   Ruxer Jr , Robert L ^a,f   Boehm, Kristi A ^a   Asmar, Lina ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b Ocala Oncology   (United States)

^c Northern Arizona Hematology Oncology   (United States)

^d ROCKY MOUNTAIN CANCER CENTERS   (United States)

^e Tyler Cancer Center   (United States)

^f TEXAS ONCOLOGY   (United States)

Author keywords

Monoclonal antibodies; Quality of life; Targeted therapy; XELIRI

Indexed keywords

CAPECITABINE; CETUXIMAB; IRINOTECAN;

ABDOMINAL PAIN; ABSCESS; ACUTE KIDNEY FAILURE; ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANAPHYLAXIS; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPNEA; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; ELECTROLYTE DISTURBANCE; FEMALE; FRACTURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPOMAGNESEMIA; INTESTINE OBSTRUCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; RASH; SCORING SYSTEM; SKIN MANIFESTATION; SOMNOLENCE; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; URINARY TRACT INFECTION; VOMITING;

EID: 58849087286     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.052     Document Type: Article

References (23)

1. American Cancer Society. Detailed Guide: Colon and Rectum Cancer. What Are the Key Statistics for Colorectal Cancer? Available at: http://www.cancer. org/doc-root/CRI/content/CRI-2-4-1X-What-are-the-key-statistics-for-colon-and- rectum-cancer.asp?sitearea. Accessed: June 16, 2008.
2. Cartwright T, Lopez T, Vukelja SJ, et al. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 2005; 5:50-6.
3. Patt YZ, Lin E, Liebman J, et al. Capecitabine plus irinotecan: a highly active first-line treatment for metastatic colorectal cancer (MCRC). Presented at: the American Society of Clinical Oncology: 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Franciso, California. Abstract 228.
4. DeLord JP, Peirga JY, Dieras V, et al. Dose escalation and pharmacokinetic study of capecitabine (Xeloda) and irinotecan (CPT-11) in gastrointestinal tumors: preliminary results. Proc Am Soc Clin Oncol 2003; 21:100a (Abstract 397).
5. Kerr D. Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. Oncology 2002; 16(suppl):12-5.
6. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 95:205-16.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958; 53:457-81.
8. Michalaki V, Gennatas C, Gennatas S, et al. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. J Clin Oncol 2007; 25(18 suppl):633s (Abstract 14602).
9. Rea DW, Nortier JW, Ten Bokkel Huinink WW, et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 2005; 16:1123-32.
10. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24:4914-21.
11. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
12. Gebbia V, Del Prete S, Borsellino N, et al. Efficacy and safety of cetuximab/iri- notecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer 2006; 5:422-8.
13. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetux- imab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
14. Cassano A, Basso M, Quirino M, et al. Cetuximab and irinotecan in second- and third-line treatment of advanced colorectal cancer patients. Presented at: the American Society of Clinical Oncology: the 2007 Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, Florida. Abstract 451.
15. Stein A, Al-Batran SE, Arnold D, et al. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. Presented at: the American Society of Clinical Oncology: the 2007 Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, Florida. Abstract 47.
16. Buzaid A, de Cerqueira Mathias C, Perazzo F, et al. Preliminary data from a phase II study of cetuximab with irinotecan in heavily pretreated patients with epidermal growth factor (EGFR)-expressing metastatic colorectal cancer (mCRC): LABEL. J Clin Oncol 2007; 25(18 suppl):626s (Abstract 14521).
17. Mathias C, Buzaid A, Perazzo F, et al. Phase II study of cetuximab with irinotecan in patients with epidermal growth factor (EGFR)-expressing metastatic colorectal cancer (mCRC): LABEL preliminary data. Presented at: the American Society of Clinical Oncology: the 2007 Gastrointestinal Cancers Symposium; January 1921, 2007; Orlando, Florida. Abstract 293.
18. Pfeiffer P, Bjerregaard JK, Qvortrup C. Biweekly cetuximab (Cet) and irinotecan (Iri) as third-line therapy in patients with advanced colorectal cancer (ACRC). Presented at: the American Society of Clinical Oncology: the 2007 Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, Florida. Abstract 305.
19. Folprecht G, Lutz MP, Schöffski P, et al. Cetuximab and irinotecan/5-fluoroura- cil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17:450-6.
20. Heinemann V, Fischer Von Weikersthal L, Moosmann N, et al. Cetuximab + capecitabine + irinotecan (CCI) versus cetuximab + capecitabine + oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): preliminary results of a randomized phase II trial of the AIO CRC Study Group. J Clin Oncol 2006; 24(18 suppl):158s (Abstract 3550).
21. Heinemann V, Moosmann N, Vehling-Kaiser U, et al. XELIRI plus cetuximab versus XELOX plus cetuximab for first-line therapy of metastatic colorectal cancer (CRC): a randomized trial of the AIO CRC Study Group. Presented at: the American Society of Clinical Oncology: the 2007 Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, Florida. Abstract 278.
22. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 2007; 25(18 suppl):164s (Abstract 4000).
23. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779-86.